In:
Frontiers in Psychiatry, Frontiers Media SA, Vol. 14 ( 2023-8-22)
Abstract:
Transcranial direct current stimulation (tDCS) is an emerging treatment for major depression. We recruited participants with moderate-to-severe major depressive episodes for an observational clinical trial using Soterix Medical's tDCS telehealth platform as a standard of care. The acute intervention consisted of 28 sessions (5 sessions/week, 6 weeks) of the left anodal dorsolateral prefrontal cortex (DLPFC) tDCS (2.0 mA × 30 min) followed by a tapering phase of weekly sessions for 4 weeks (weeks 7–10). The n = 16 completing participants had a significant reduction in depressive symptoms by week 2 of treatment [Montgomery–Åsberg Depression Rating Scale (MADRS), Baseline : 28.00 ± 4.35 vs. Week 2: 17.12 ± 5.32, p & lt; 0.001] with continual improvement across each biweekly timepoint. Acute intervention responder and remission rates were 75 and 63% and 88 and 81% following the taper period (week 10).
Type of Medium:
Online Resource
ISSN:
1664-0640
DOI:
10.3389/fpsyt.2023.1199773
DOI:
10.3389/fpsyt.2023.1199773.s001
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2023
detail.hit.zdb_id:
2564218-2
Permalink